In a groundbreaking development for nephrology research, the American Kidney Fund (AKF) has announced the recipients of the prestigious 2026 Clinical Scientist in Nephrology (CSN) Program grants: Dr. Sophie Claudel and Dr. Liz Kiernan. This program, renowned for its commitment to funding early-career nephrologists, plays a vital role in propelling innovative research aimed at transforming the diagnosis, treatment, and prognosis for chronic kidney disease (CKD) patients. The selection of these two researchers underscores AKF’s dedication to fostering cutting-edge studies that promise significant advancements in understanding the intricate mechanisms of kidney disease and associated complications.
Dr. Sophie Claudel, currently a nephrology fellow at Boston Medical Center and a clinical instructor at Boston University Chobanian & Avedisian School of Medicine, has been awarded the Akebia CSN Fellowship. Her research centers on elucidating the complex relationship between chronic kidney disease and cardiovascular disease, a co-morbidity that remains one of the leading causes of mortality in CKD patients. Through detailed molecular and proteomic analyses, Dr. Claudel aims to uncover the pathways that contribute to vascular injury triggered by early kidney damage, with the ultimate objective of identifying novel therapeutic targets that could arrest or reverse disease progression.
Concurrently, Dr. Liz Kiernan, a clinical research fellow at the University of Washington School of Medicine, focuses her expertise on endothelial cell function in the context of kidney diseases. Using state-of-the-art single-cell sequencing technologies, Dr. Kiernan endeavors to map specific molecular markers indicative of endothelial injury. The significance of her work lies in its potential to revolutionize diagnostics by enabling non-invasive methods to detect kidney pathology much earlier. Furthermore, it supports the development of precise, personalized treatment strategies to mitigate damage associated with diabetic nephropathy and acute kidney injury.
Since its launch in 1989, the CSN Program has been pivotal in advancing nephrology research by providing critical funding to young investigators who later emerge as leaders and mentors within the kidney health community. The success stories stemming from this program underscore its importance in nurturing scientific talent dedicated to unraveling the complexities of kidney disease pathways and treatment modalities. The 2026 fellowships awarded to Dr. Claudel and Dr. Kiernan are generously financed through partnerships with Akebia Therapeutics and the HFO Foundation, whose contributions enable sustained investment in transformative kidney research.
Dr. Claudel’s investigative work carefully dissects the molecular interplay responsible for albuminuria—a hallmark of early kidney injury—and its systemic effects on blood vessels. This intersection between renal and cardiovascular health remains an underexplored frontier, particularly during the asymptomatic phase where intervention would yield maximum benefit. By focusing on proteins and signaling cascades implicated in this process, her research not only promises new avenues for early detection but also the design of innovative therapies that target kidney-vascular crosstalk before irreversible pathological damage ensues.
Similarly, Dr. Kiernan’s approach harnesses the granularity offered by advanced single-cell RNA sequencing to delineate endothelial cell heterogeneity in kidney biopsies obtained from patients suffering from diabetic kidney disease and acute kidney injury. Her aim is to identify and characterize specific transcriptomic signatures linked to endothelial dysfunction. Understanding these molecular footprints holds enormous promise in refining prognostication models and in tailoring interventions that could effectively halt or even reverse endothelial damage, thereby preserving kidney function and improving patient outcomes.
Both researchers emphasize the critical importance of early detection and intervention in kidney disease. Dr. Claudel highlights how kidney and heart diseases are interconnected through poorly understood molecular pathways that are particularly elusive during initial silent injury phases. Her research targets these early molecular events to develop interventions that could halt disease progression at a stage when treatment efficacy is highest. Dr. Kiernan, on the other hand, is driven by the potential of modern scientific tools to identify early disease markers, which she believes will usher in a new era of personalized nephrology where treatment is specifically tailored to molecular profiles.
Their complementary research strategies represent a holistic assault on the multifactorial nature of CKD and its cardiovascular complications. Dr. Claudel’s proteomic and genomic focus on systemic vascular injury dovetails with Dr. Kiernan’s molecular dissection of localized endothelial dysfunction, together forming a broader understanding of the pathophysiological networks at play. This synergy holds promise not just for academic insights but also for clinical applications that will significantly improve early diagnosis, disease monitoring, and targeted treatment options for millions globally.
Underpinning their research is a firm commitment to the mission of the American Kidney Fund, which seeks not only to alleviate the burden of kidney disease but also to cultivate scientific innovation capable of driving foundational change in patient care. The AKF’s investment in these early-career investigators reaffirms the fund’s strategic focus on research that addresses the unmet medical needs of vulnerable patient populations suffering from chronic kidney disease and its devastating sequelae.
Dr. Claudel brings to her fellowship a robust background combining clinical training with research experience at the National Institutes of Health, complemented by her work at Boston Medical Center. Her multidisciplinary expertise equips her to bridge clinical nephrology with molecular science, a critical skill set to translate laboratory findings into therapeutic advancements that can be rapidly implemented in patient care.
Likewise, Dr. Kiernan’s clinical research fellowship at the University of Washington is supported by a comprehensive academic journey beginning with a Bachelor of Science in biochemistry, followed by medical training and rigorous internal medicine residency and leadership roles. This diverse academic foundation and clinical experience empower her to integrate cutting-edge molecular techniques into research that holds direct translational potential for improved clinical diagnostics and therapeutics in kidney disease.
The AKF’s CSN Program not only fosters scientific excellence but also facilitates important collaborations and mentorship that are vital for sustaining innovation within nephrology. By supporting researchers like Dr. Claudel and Dr. Kiernan, who combine cutting-edge scientific methodology with a strong patient-centered ethos, the program continues its legacy of nurturing the leaders who will define the future of kidney care.
The endorsement of this program by prominent stakeholders such as Akebia Therapeutics and the HFO Foundation further accentuates the importance of public-private partnerships in advancing nephrology research. These collaborations enable substantial resource allocation towards projects that have the highest potential for clinical impact, ultimately benefiting patients at every stage of kidney disease progression.
In summary, the award of the 2026 Clinical Scientist in Nephrology Program fellowships to Dr. Claudel and Dr. Kiernan heralds a new chapter in kidney disease research, marked by a sophisticated understanding of molecular pathophysiology and a commitment to precision medicine. Their groundbreaking work promises to bridge crucial knowledge gaps in the nexus of kidney and cardiovascular diseases and to catalyze the development of personalized diagnostic tools and therapeutic interventions. This innovative research trajectory is poised to significantly enhance quality of life and survival for those affected by chronic kidney disease.
Subject of Research: Molecular and cellular mechanisms linking chronic kidney disease to cardiovascular complications, focusing on early kidney damage and endothelial injury using proteomic analyses and single-cell sequencing.
Article Title: American Kidney Fund Awards 2026 Clinical Scientist in Nephrology Fellowships to Dr. Sophie Claudel and Dr. Liz Kiernan
News Publication Date: April 21, 2026
Web References:
https://www.kidneyfund.org/professionals-and-research/clinical-scientist-nephrology-program
https://www.kidneyfund.org/
Keywords: Chronic kidney disease, cardiovascular disease, nephrology research, endothelial injury, albuminuria, single-cell sequencing, molecular diagnostics, personalized medicine, kidney and heart disease connection, early detection, targeted therapies, kidney biopsy
Tags: American Kidney Fund research grantsBoston Medical Center nephrology researchchronic kidney disease and cardiovascular disease linkClinical Scientist in Nephrology Program 2026early-career nephrologists fundingendothelial cell signaling in kidney diseasekidney disease comorbidities mortalitykidney-heart disease molecular pathwaysnephrology research innovationsnovel therapeutic targets for CKDproteomic analysis of vascular injuryvascular injury in early kidney damage
